Cellogen Therapeutics Expands Viral Vector Capacity in India

Why it matters

- This expansion is part of a broader strategy for Cellogen Therapeutics, a Delhi-based startup that recently secured a patent for an indigenously developed bi-specific CAR-T cell therapy and aims to reduce treatment costs by over 90%. - The move taps into a rapidly growing domestic market; India's viral vector and plasmid DNA manufacturing sector was valued at $241.5 million in 2025 and is projected to reach $796.9 million by 2033, growing at a 16.2% CAGR. - A critical challenge in the lentiviral vector upstream process that this facility will address is "retro-transduction

Key numbers

• The company is currently hiring for roles related to the scale-up of its 500L+ lentiviral vector facility, focusing on upstream and downstream processing under GMP compliance.
• - This expansion is part of a broader strategy for Cellogen Therapeutics, a Delhi-based startup that recently secured a patent for an indigenously developed bi-specific CAR-T cell therapy and aims to reduce treatment costs by over 90%.
• The move taps into a rapidly growing domestic market; India's viral vector and plasmid DNA manufacturing sector was valued at $241.5 million in 2025 and is projected to reach $796.9 million by 2033, growing at a 16.2% CAGR.

What happens next

• This expansion is part of a broader strategy for Cellogen Therapeutics, a Delhi-based startup that recently secured a patent for an indigenously developed bi-specific CAR-T cell therapy and aims to reduce treatment costs by over 90%.
• A critical challenge in the lentiviral vector upstream process that this facility will address is "retro-transduction Cellogen Therapeutics is expanding its viral vector manufacturing capabilities in India.

Sources

• is expanding
• This expansion is part
• The move taps into

Quick answers